Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Biologics registers in RA: methodological aspects, current role and future applications.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers.[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyThe British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.The BSRBR-RA at 15 years.Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritisThe incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritisReduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review.Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].[Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer].Human Papillomavirus-Induced Cancer: Late Relapse in a Patient Treated With Tumor Necrosis Factor-Alpha Inhibitor.The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.Late Recurrence of Low-Risk Stage II Colorectal Cancer Shortly After Etanercept.[Systemic treatments for psoriasis and psoriatic arthritis].Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
P2860
Q28074148-A1A25C55-613A-4A2F-84FB-BE95EE672C18Q30234303-FA9777BF-CA2E-4CE9-A2B9-07EC8008F9B2Q30397234-5CEB2D44-8AB0-4164-B119-1D4A8D8C6551Q30936806-B3F6A79E-218E-4578-B5D9-31E107C58940Q31036951-8A114AAF-75F5-4252-9FD3-CDFDADECBF48Q34363241-F2B11D2F-66DD-4583-B59B-7E7E721FEF2CQ35813092-749B7E7D-AB86-47A4-8C06-F100C41133A4Q35838797-0041D3B1-EEEA-42EC-B3B0-A75FD1643BEFQ37333943-512DDB5C-0B0F-4824-808C-901EAE37A1CEQ37356217-3135D9C8-9BBC-4934-A576-631D13F50010Q37383424-E085E1E7-0275-4284-836C-E03B6A16020CQ37599165-1809B932-8225-486D-8561-1EC277765C95Q37622219-A1ACA7FB-5772-4014-A779-CF76E9EEBFCFQ37656273-223A2193-1C2D-4541-A7B9-BF5989ACFA3EQ38672588-82ED6878-9B28-4A84-99E3-DD2AC6F1A08FQ38673326-B4B9B2D2-D359-4E83-A3CD-5B122BCBE111Q38755133-0A92AA70-DD00-421A-9F1E-13C36FEEF5DEQ39309064-CD3749E8-DB09-45B9-A6FC-E24639E3D1F7Q40000074-3D1B9A70-1C6D-48A8-BC10-A070100B12D5Q40179378-3EB81FC6-694B-4595-9E12-D01D341F3047Q40934508-F0B5CC3C-E39D-4735-8934-8C490152EF44Q40965334-E584A28A-BB2E-4659-A680-1106362FC002Q40988091-83C1F3C0-EADC-4DB3-99DF-C8C5893355FEQ47159355-238C000E-10E1-479E-9838-123D96D3EACDQ47620758-93C0F6AE-7B62-45E2-BBC4-0A0D9CBE30A1Q48276935-A403376E-EDCE-467B-8E89-C527E20592E1Q52851716-7CFD610B-7E6D-4965-971C-265E24772CE2Q55153984-57FB8486-EEC3-49E8-BCD0-41D6A68C18A8Q57245381-489814A9-5B05-4039-BAEF-A804AFE9E94C
P2860
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@ast
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@en
type
label
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@ast
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@en
prefLabel
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@ast
Risk of solid cancer in patien ...... ster for Rheumatoid Arthritis.
@en
P2093
P2860
P50
P1476
Risk of solid cancer in patien ...... ister for Rheumatoid Arthritis
@en
P2093
Audrey L S Low
BSRBR Control Centre Consortium
Kath D Watson
Kimme L Hyrich
Louise K Mercer
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204851
P407
P577
2014-03-31T00:00:00Z